D-Link DWA-556 Xtreme N PCI Express Desktop Adapter ? Buy Now

The D-Link Xtreme N PCI Express Desktop Adapter (DWA-556) is a draft 802.11n wireless client that delivers unrivaled wireless performance for your PCI Express-enabled desktop puter. The PCIe interface provides superior performance over a standard PCI interface. This wireless adapter delivers up to 14x faster speeds and 6x farther range than 802.11g while staying backward patible with 802.11g and 802.11b works. Once connected you can share a high-speed Inter connection photos files music videos printers and storage.Primary InformationNetworking Type?:??Network adapter?Form Factor?:??Plug-in card?Networking Interface?:??PCI Express x1?Data Transfer Rate?:??N/A?Data Link Protocol?:??IEEE 802.11b; IEEE 802.11g; IEEE 802.11n (draft)?Connectivity Technology?:??Wireless?Networking / Compliant Standards?:??IEEE 802.11b IEEE 802.11g IEEE 802.11n (draft)?Dimensions&MiscellaneousDepth?:??4.7 Inch?Height?:??2.7 Inch?ExpansionInterfaces & Connections?:??Networ

Product Features:

• Wireless N connectivity for superior wireless performance, clarity, and coverage
• Single-band Wireless N Connectivity
• Wi-Fi Protected Setup (WPS) for secure, simple 1-button setup
• Access secure wireless networks using advanced WPA or WPA2 encryption
• Easy to install and use with D-Link?s new Quick Adapter Setup Wizard
• Backward compatible with existing 802.11g networks

Product Reviews:

Adapter, Desktop, DLink, DWA556, Express, Xtreme

About Souvik

Web Developer and SEO Specialist with 7+ years of experience in open source web development. He is also the moderator of this blog (www.rswebsols.com)

View all posts by Souvik ?

mega millions lottery jackpot winning numbers mega millions megamillions drawing olbermann mega millions march 30 lucky numbers

Filed under relaxing | Tags: IEEE, mega millions lottery, pci express x1 | Comment (0)

Islanders help basketball team to top finish | Sports brief

Contributed photo

The 5th grade ECBA Swish team took first place at the Puget Sound Classic basketball tournament.

By MEGAN MANAGAN
Mercer Island Reporter Reporter
May 15, 2012 ? Updated 3:12 PM?

Mercer Island residents Angelina Barokas and Emma Pfeiffer, both members of the ECBA 5th grade Swish team, helped the team to a first place finish in the second annual Puget Sound Classic basketball tournament in mid-May.

Also playing in the tournament was the seventh grade ECBA Thunder team, which finished second overall. Islanders Gracie Cannon and Aolani Calderon are members of the team.

?

Contact Mercer Island Reporter Reporter Megan Managan at mmanagan@mi-reporter.com or (206) 232-1215 ext. 5054.

taylor momsen xbox live update joan rivers gary carter dies oolong tea survivor one world lil kim

Filed under relaxing | Tags: basketball, mercer island reporter, taylor momsen | Comment (0)

Facebook IPO shares tough task for small investors

CHICAGO (AP) ? Hoping to get in on Facebook‘s hotly anticipated public stock offering? You’ll need Facebook friends at very high levels ? or a lot of money.

Most people who like the idea of owning Facebook’s stock will have difficulty getting it at the offer price, currently expected at $28 to $35 a share. Unless you know the right people at Facebook, you’ll likely need to have a large, active account with one of the big banks or brokerage firms directly involved in the stock sale.

Otherwise, you can take your chances by buying shares after the initial public offering is completed, when Facebook begins trading on the Nasdaq Stock Market under the ticker symbol “FB.” That’s likely to happen Friday.

Doing it that way typically means paying much more for the stock, however. And heavy demand skews the early stock price, leaving an investor vulnerable to the risk of a big drop.

Jerome Cleary isn’t deterred. One of a legion of Facebook fans, he has never wanted to own a stock as much as he wants to buy this one. Cleary, a standup comedian in Los Angeles, says he has already signed up for an account with a discount online brokerage so he’ll be ready.

“I know you should buy stock in what you know and like,” Cleary says. “I feel that because they have an incredible mass of wealth and such growing popularity, the stock really may pay off.”

Facebook Inc.’s IPO is expected to be the largest ever for an Internet company. It’s expected to raise as much as $11.8 billion for Facebook and its early investors ? far more than the $1.67 billion raised in Google Inc.’s 2004 IPO.

Analysts say there’s so much interest in Facebook’s stock that some underwriters are closing their books as early as Tuesday. This means they won’t be taking any more orders from potential buyers. The IPO is expected to be completed late Thursday, with shares available for trading Friday.

Scott Sweet, the owner of advisory firm IPOBoutique, says the high demand also means that Facebook might raise the per-share price above $35, the high end of the range Facebook currently expects. Facebook and the IPO’s lead underwriter, Morgan Stanley, declined to comment.

If you’re thinking of investing in Facebook, here are some things to consider.

? IPO SHARES

Facebook and its early investors are selling more than 337 million shares, but those shares are parceled out very carefully, away from the public’s eyes.

Typically individuals get to buy no more than 10 percent to 20 percent of shares sold at an IPO’s offering price. The vast majority will go to company insiders, institutional investors, the underwriters selected by the company to handle the process and preferred clients of all of them.

Morgan Stanley leads the team of 33 underwriters selected for the Facebook offering, followed by JPMorgan Chase and Goldman Sachs.

The inclusion of online broker E-Trade Financial Corp. as an underwriter was seen as a glimmer of hope that Facebook might make more shares available than usual for retail investors through discount brokerages. But chances of getting any are very slim regardless.

? ELIGIBILITY

The big online brokerages have been taking formal requests from customers for Facebook’s IPO. They anticipate they’ll get their own allocations from one source or another, such as one of the underwriters. E-Trade, Fidelity Investments, Charles Schwab and TD Ameritrade, among others, have been fielding abundant queries.

But the requirements they set on who gets them eliminate most small investors.

Fidelity, which will be getting an undetermined number of shares from underwriter Deutsche Bank, says customers should have $500,000 in their accounts and have made 36 trades in the past year to be eligible. Ameritrade’s account requirements are at least $250,000 and 30 trades in three months. Schwab’s are a minimum $100,000 or 36 trades in the past year, but the firm says it also has other requirements.

Even meeting the requirements is no guarantee of getting shares.

Joshua Freeman, an information technology professional in New York, knows investing in Facebook is risky. But he believes “it’s got a pretty good shot to make some money.”

He has been investing with E-Trade since the mid-1990s and has about $200,000 in his account. But he’s pessimistic about his request for 100 Facebook shares at the IPO price, given the frenzy over the offering.

“I’m hoping to get some but I’m guessing that I won’t,” Freeman says. “I’m hoping it follows the trend and goes crazy and then dips a little bit. If it does that, I may buy some on the open market.”

? OPEN MARKET

If you strike out as an insider, it will still be easy, but expensive, to buy shares on the open market. Open and fund an account with a brokerage. Then for a transaction fee of as little as $7, you can buy Facebook stock at whatever price the market demand has driven it.

Be aware that the price could jump significantly by the time you place your order. Among last year’s hottest IPOs, Groupon Inc. soared in the opening minutes and gained 31 percent on the first day of trading. Zillow Inc. jumped 79 percent and LinkedIn Corp. more than doubled.

Investors buying on the open market miss much or perhaps all of any first-day “pop.”

The first-day market price of newly issued stocks during the past decade has been an average 11 percent higher than the offer price, according to University of Florida finance professor Jay Ritter.

For investors buying at the offer price, Facebook is likely to produce a gain on the first day, he says. But once it starts trading, investors should think of it as just another stock that’s as likely to go down as up.

Consider this: Groupon, which went public at an IPO price of $20 six months ago, soared as high as $31.14 on the first day. It closed Monday at $11.73, 41 percent below the offer price.

As for the idea of buying the stock at a low point a few months from now, Ritter says that has not worked historically as a reliable strategy with IPOs. And this one’s starting at a very high price, he emphasizes, with optimistic expectations of future growth built into it.

The only sure winners, he says, will be Facebook employees and venture capitalists who invested in the company when it was private.

James Breyer and his Accel Partners firm, investors since 2005, stand to make up to $1.34 billion from the 38.2 million shares they are offering. Zynga Inc. CEO Mark Pincus, a Facebook investor since 2004, stands to make up to $35 million on 1 million shares.

“The time to buy Facebook was five years ago,” Ritter says.

charlotte bobcats denver broncos new york rangers nfl mock draft 2012 norfolk island michael brockers lisa marie presley

Filed under relaxing | Tags: IPO | Comment (0)

James Wilks, TUF winner and UFC veteran, retires after warnings of possible paralysis

“The Ultimate Fighter” season nine winner James Wilks announced his retirement from MMA after doctors advised him he could become paralyzed if he continued to fight.

Wilks had a serious knee injury that kept him out of the Octagon. His last bout was a loss to Claude Patrick in October of 2010. When that healed, a neck injury from his rugby-playing days flared up and Wilks realized how serious previous warning signs were.

“I had problems in a couple of the fights that I didn’t really talk about,” he said. “In one of the fights, I got hit, and the whole left side of my body went numb, all the way down to the toes.”

Even with the doctor’s warnings, Wilks called the decision difficult, particularly because he went out on a loss. He went 1-2 in the UFC after beating DaMarques Johnson in the TUF finale. As more fighters age, they will be faced with the issue of retirement. Kudos to Wilks for being strong enough to walk away before he was damaged permanently.

christmas photo cards ar 15 costco kmart urban meyer ohio state traffic report traffic report

Filed under relaxing | Tags: TUF | Comment (0)

Delivery system for gene therapy may help treat arthritis

ScienceDaily (May 15, 2012) ? A DNA-covered submicroscopic bead used to deliver genes or drugs directly into cells to treat disease appears to have therapeutic value just by showing up, researchers report.

Within a few hours of injecting empty-handed DNA nanoparticles, Georgia Health Sciences University researchers were surprised to see increased expression of an enzyme that calms the immune response.

In an animal model of rheumatoid arthritis, the enhanced expression of indoleomine 2,3 dioxygenase, or IDO, significantly reduced the hallmark limb joint swelling and inflammation of this debilitating autoimmune disease, researchers report in the study featured on the cover of The Journal of Immunology.

“It’s like pouring water on a fire,” said Dr. Andrew L. Mellor, Director of the GHSU’s Medical College of Georgia Immunotherapy Center and the study’s corresponding author. “The fire is burning down the house, which in this case is the tissue normally required for your joints to work smoothly,” Mellor said of the immune system’s inexplicable attack on bone-cushioning cartilage. “When IDO levels are high, there is more water to control the fire.”

Several delivery systems are used for gene therapy, which is used to treat conditions including cancer, HIV infection and Parkinson’s disease. The new findings suggest the DNA nanoparticle technique has value as well for autoimmune diseases such as arthritis, type 1 diabetes and lupus. “We want to induce IDO because it protects healthy tissue from destruction by the immune system,” Mellor said.

The researchers were exploring IDO’s autoimmune treatment potential by inserting the human IDO gene into DNA nanoparticles. They hoped to enhance IDO expression in their arthritis model when Dr. Lei Huang, Assistant Research Scientist and the paper’s first author, serendipitously found that the DNA nanoparticle itself produced the desired result. Exactly how and why is still being pursued. Early evidence suggests that immune cells called phagocytes, white blood cells that gobble up undesirables like bacteria and dying cells, start making more IDO in response to the DNA nanoparticle’s arrival. “Phagocytes eat it and respond quickly to it and the effect we measure is IDO,” Mellor said.

Dr. Tracy L. McGaha, GHSU immunologist and a co-author on the current study, recently discovered that similar cells also prevented development of systemic lupus erythematosus in mice.

Follow-up studies include documenting all cells that respond by producing more IDO. GHSU researchers already are working with biopolymer experts at the Massachusetts Institute of Technology, the University of California, Berkeley and the Georgia Institute of Technology to identify the optimal polymer.

The polymer used in the study is not biodegradable so the researchers need one that will eventually safely degrade in the body. Ideally, they’d also like it to target specific cells, such as those near inflamed joints, to minimize any potential ill effects.

“It’s like a bead and you wrap the DNA around it,” Mellor said of the polymer. While the DNA does not have to carry anything to get the desired response in this case, DNA itself is essential to make cells express IDO. To ensure that IDO expression was responsible for the improvements, they also performed experiments in mice given an IDO inhibitor in their drinking water and in mice genetically altered to not express IDO. “Without access to the IDO pathway, the therapy no longer works,” Mellor said.

Drs. Andrew Mellor and David Munn reported in 1998 in the journal Science that the fetus expresses IDO to help avoid rejection by the mother’s immune system. Subsequent studies have shown tumors also use IDO for protection and clinical trials are studying the tumor-fighting potential of an IDO inhibitor. On the flip side, there is evidence that increasing IDO expression can protect transplanted organs and counter autoimmune disease.

Mellor is the Bradley-Turner and Georgia Research Alliance Eminent Scholar in Molecular Immunogenetics at MCG. The research was funded by the Carlos and Marguerite Mason Trust and the National Institutes of Health and a patent is pending on the findings.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

---

Story Source:

The above story is reprinted from materials provided by Georgia Health Sciences University. The original article was written by Toni Baker.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

---

Journal Reference:

1. L. Huang, H. P. Lemos, L. Li, M. Li, P. R. Chandler, B. Baban, T. L. McGaha, B. Ravishankar, J. R. Lee, D. H. Munn, A. L. Mellor. Engineering DNA Nanoparticles as Immunomodulatory Reagents that Activate Regulatory T Cells. The Journal of Immunology, 2012; 188 (10): 4913 DOI: 10.4049/jimmunol.1103668

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

happy holidays norad how to carve a turkey how to cook a turkey yorkshire pudding larry the cable guy miracle on 34th street

Filed under relaxing | Tags: expression | Comment (0)

This Iron Man Action Figure Is Your Catchphrase-And-Missile-Spewing Deal of the Day [Dealzmodo]